All Stories

  1. Comparison between proactive and retroactive models of medication reconciliation in patients hospitalized for acute decompensated heart failure
  2. Clinical considerations on monkeypox antiviral medications: An overview
  3. Correction to: Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial
  4. Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial
  5. Global Variations in Heart Failure
  6. Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial
  7. Review of Prediabetes
  8. SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
  9. Effect of Caffeine Consumption on Cardiovascular Disease: An Updated Review
  10. Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial
  11. Current evidence of COVID-19 vaccination-related cardiovascular events
  12. Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
  13. Enoxaparin’s potential mechanisms against SARS-CoV-2
  14. Monkeypox treatment: Current evidence and future perspectives
  15. A commentary on “Unexpected sudden rise of human monkeypox cases in multiple non-endemic countries amid COVID-19 pandemic and salient counteracting strategies: Another potential global threat?” (Int J Surg 2022;103:106705)
  16. Synthesis, characterization, and the investigation of the applicability of citric acid functionalized Fe2O3 nanoparticles for the extraction of carvedilol from human plasma using DFT calculations and clinical samples analysis
  17. New Variants of SARS‐CoV‐2 and Next Generation of COVID‐19 Treatments
  18. The role of antigen-presenting cells in the pathogenesis of COVID-19
  19. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
  20. SARS-CoV-2 and probable lung cancer risk
  21. The impact of metformin on cardiac troponin-I and ST resolution in patients with ST elevation myocardial infarction undergoing thrombolytic therapy
  22. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
  23. Hypertensive Crisis Following COVID‐19 Vaccination
  24. Investigational antiviral drugs for the treatment of COVID-19 patients
  25. Tocilizumab in COVID-19 management: addressing time of starting treatment
  26. Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review
  27. Colchicine for the Prevention of Myocardial Injury Following Elective PCI: A Randomized Clinical Trial
  28. Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment
  29. Potential Roles of Vitamins in the Management of COVID-19: A Comprehensive Review
  30. Therapeutic Application of Corticosteroids in COVID‐19: A Focus on Optimum Dose and Duration of Therapy
  31. Preventive use of Calcitriol versus cholecalciferol on biochemical markers of Metabolic Bone Disease (MBD) in very low birth weight infants: a pilot randomized clinical trial
  32. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
  33. SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
  34. The effects of Allopurinol on levels of cardiac troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial
  35. Pharmacist-Directed Self-Management of Blood Pressure Versus Conventional Management in Patients with Hypertension: A Randomized Control Trial
  36. Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
  37. Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
  38. A comprehensive review on sarilumab in COVID-19
  39. The Impact of Clinical Pharmacist Interventions on Medication Errors Management in the Postoperative Cardiac Intensive Care Unit
  40. The Randomized Clinical Trial of Pentoxifylline for Reduction of Blood Pressure in Patients with Primary Hypertension
  41. A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome
  42. Anticoagulation in COVID-19: DDI Perspective
  43. Clopidogrel Adherence to AHA/ACC Guideline in Patients with Open Heart Surgery in a Tertiary Heart Center
  44. Effects of Adding Pentoxifylline to Captopril on Primary Hypertension: A Pilot Randomized Clinical Trial
  45. Curcumin for the prevention of myocardial injury following elective percutaneous coronary intervention; a pilot randomized clinical trial
  46. Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial
  47. Detection and Management of Common Medication Errors inInternal Medicine Wards: Impact on Medication Costs and Patient Care
  48. Isotretinoin; A review on the Utilization Pattern in Pregnancy
  49. Procalcitonin May Not Discriminate Between Sepsis and Non-Infective Systemic Inflammatory Response Syndrome (SIRS) in Heterogonous Critically Ill Patients
  50. Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial
  51. Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial
  52. Measurement and Comparison of Inpatient Antibiotic Use in Five Different Hospitals in Tabriz
  53. Antimicrobial susceptibility patterns among bacteria isolated from intensive care units of the largest teaching hospital at the northwest of Iran
  54. The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention
  55. The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs-CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial
  56. A review of Vitamin D effects on common respiratory diseases: Asthma, chronic obstructive pulmonary disease, and tuberculosis
  57. anticoagulation management services
  58. The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism
  59. The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population
  60. A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention
  61. A two-year utilization of the pharmacist-operated drug information center in Iran
  62. A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation
  63. The evaluation of isotretinoin induced adverse drug reactions